6549 Stock Overview
TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan.
TaiwanJ Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$10.05|
|52 Week High||NT$15.00|
|52 Week Low||NT$9.07|
|1 Month Change||-9.46%|
|3 Month Change||-23.86%|
|1 Year Change||-24.44%|
|3 Year Change||-15.55%|
|5 Year Change||-44.17%|
|Change since IPO||-79.90%|
Recent News & Updates
Companies Like TaiwanJ Pharmaceuticals (GTSM:6549) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Will TaiwanJ Pharmaceuticals (GTSM:6549) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
|6549||TW Biotechs||TW Market|
Return vs Industry: 6549 underperformed the TW Biotechs industry which returned 7.3% over the past year.
Return vs Market: 6549 underperformed the TW Market which returned -0.7% over the past year.
|6549 Average Weekly Movement||4.5%|
|Biotechs Industry Average Movement||5.2%|
|Market Average Movement||4.6%|
|10% most volatile stocks in TW Market||8.2%|
|10% least volatile stocks in TW Market||2.2%|
Stable Share Price: 6549 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 6549's weekly volatility (4%) has been stable over the past year.
About the Company
TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company also develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis.
TaiwanJ Pharmaceuticals Fundamentals Summary
|6549 fundamental statistics|
Is 6549 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6549 income statement (TTM)|
|Cost of Revenue||NT$0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.17|
|Net Profit Margin||-56.32%|
How did 6549 perform over the long term?See historical performance and comparison
Is TaiwanJ Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6549's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6549's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: 6549 is unprofitable, so we can't compare its Price-To-Earnings Ratio to the TW Biotechs industry average.
PE vs Market: 6549 is unprofitable, so we can't compare its Price-To-Earnings Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6549's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6549 is overvalued based on its Price-To-Book Ratio (4.6x) compared to the TW Biotechs industry average (3.8x).
How is TaiwanJ Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TaiwanJ Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has TaiwanJ Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6549 is currently unprofitable.
Growing Profit Margin: 6549 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6549 is unprofitable, but has reduced losses over the past 5 years at a rate of 43.8% per year.
Accelerating Growth: Unable to compare 6549's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6549 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).
Return on Equity
High ROE: 6549 has a negative Return on Equity (-7.6%), as it is currently unprofitable.
How is TaiwanJ Pharmaceuticals's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 6549's short term assets (NT$88.4M) exceed its short term liabilities (NT$6.9M).
Long Term Liabilities: 6549 has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 6549 is debt free.
Reducing Debt: 6549 has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6549 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6549 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 40.9% each year
What is TaiwanJ Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6549's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6549's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6549's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6549's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 6549 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Mr. Hung-Chang Yuan, also known as Rich, has been General Manager of TaiwanJ Pharmaceuticals Co., Ltd. since June 2018. Mr. Yuan served as Chief Financial Officer of TaiwanJ Pharmaceuticals Co., Ltd.since...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
TaiwanJ Pharmaceuticals Co., Ltd.'s employee growth, exchange listings and data sources
- Name: TaiwanJ Pharmaceuticals Co., Ltd.
- Ticker: 6549
- Exchange: TPEX
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: NT$754.976m
- Shares outstanding: 75.12m
- Website: https://www.taiwanj.com
Number of Employees
- TaiwanJ Pharmaceuticals Co., Ltd.
- No.2 ShengYi Road
- Room D207, Section-2
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.